Fact Sheet  Download PDF

Pioneering the next generation of immunotherapies

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) immunotherapeutics that deliver engineered tumor antigens, which stimulate multiple, simultaneous, immunological mechanisms to fight cancer.  Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK.  The Company’s technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.  Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn